- ImmuneOncia Therapeutics signed a manufacturing agreement with Lonza for late-stage clinical supply of its monoclonal antibody Danburstotug (IMC-001).
- Lonza will provide drug substance and drug product development and manufacturing across its UK and Switzerland sites.
ImmuneOncia Therapeutics has entered into a manufacturing agreement with Lonza to support the late-stage clinical supply of Danburstotug (IMC-001), a monoclonal antibody under investigation for cancer treatment. The agreement covers development and contract manufacturing services for both drug substance and drug product.
Under the terms of the agreement, Lonza will manufacture drug substance at its site in Slough, UK, while drug product development and clinical manufacturing will be carried out at its facilities in Basel and Stein, Switzerland. The collaboration is intended to support ImmuneOncia’s clinical development and readiness for future commercialization.
Danburstotug is a fully human monoclonal antibody designed as an immune checkpoint inhibitor targeting PD-L1. It is currently being evaluated for the treatment of relapsed or refractory NK/T-cell lymphoma, a rare cancer indication.
ImmuneOncia stated that it will leverage Lonza’s integrated CDMO and contract manufacturing capabilities, including its regulatory track record and end-to-end manufacturing network, to support development through later clinical stages and potential commercial supply.
“ImmuneOncia plans to target the rare cancer indication NKT cell lymphoma for early approval.”
Heung-Tae Kim, CEO of ImmuneOncia
